Literature DB >> 7499403

Induction of apoptosis by the c-Myc helix-loop-helix/leucine zipper domain in mouse 3T3-L1 fibroblasts.

F Kohlhuber1, H Hermeking, A Graessmann, D Eick.   

Abstract

The cellular proto-oncogene c-myc is involved in cell proliferation and transformation but is also implicated in the induction of programmed cell death (apoptosis). The c-Myc protein is a transcriptional activator with a carboxyl-terminal basic region/helix-loop-helix (HLH)/leucine zipper (LZ) domain. It forms heterodimers with the HLH/LZ protein Max and transactivates gene expression after binding DNA E-box elements. We have studied the phenotype of dominant-negative mutants of c-Myc and Max in microinjection experiments. Max mutants with a deleted or mutated basic region inhibited DNA synthesis in serum-stimulated 3T3-L1 mouse fibroblasts. In contrast, mutants of c-Myc expressing only the basic region/HLH/LZ or HLH/LZ domains rapidly induced apoptosis at low and high serum levels. Co-expression of the HLH/LZ domains of c-Myc and Max failed to do so. We suggest that the c-Myc HLH/LZ domain induces apoptosis by specific interaction with cellular factors different to Max.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7499403     DOI: 10.1074/jbc.270.48.28797

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Apoptosis: A Current Molecular Analysis.

Authors:  Dean G Tang; Arthur T Porter
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

2.  Diminished energy metabolism and enhanced apoptosis in livers of B6C3F1 mice treated with the antihepatocarcinogen rotenone.

Authors:  C Wang; J Youssef; B Saran; P G Rothberg; M L Cunningham; A Molteni; M Badr
Journal:  Mol Cell Biochem       Date:  1999-11       Impact factor: 3.396

3.  Transactivation-defective c-MycS retains the ability to regulate proliferation and apoptosis.

Authors:  Q Xiao; G Claassen; J Shi; S Adachi; J Sedivy; S R Hann
Journal:  Genes Dev       Date:  1998-12-15       Impact factor: 11.361

4.  Identification of CDK4 as a target of c-MYC.

Authors:  H Hermeking; C Rago; M Schuhmacher; Q Li; J F Barrett; A J Obaya; B C O'Connell; M K Mateyak; W Tam; F Kohlhuber; C V Dang; J M Sedivy; D Eick; B Vogelstein; K W Kinzler
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

5.  Intracellular and extracellular leukemia inhibitory factor proteins have different cellular activities that are mediated by distinct protein motifs.

Authors:  B P Haines; R B Voyle; P D Rathjen
Journal:  Mol Biol Cell       Date:  2000-04       Impact factor: 4.138

6.  Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins.

Authors:  M Bernasconi; A Remppis; W J Fredericks; F J Rauscher; B W Schäfer
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

7.  Hepatocarcinogenic potential of the glucocorticoid antagonist RU486 in B6C3F1 mice: effect on apoptosis, expression of oncogenes and the tumor suppressor gene p53.

Authors:  Jihan A Youssef; Mostafa Z Badr
Journal:  Mol Cancer       Date:  2003-01-03       Impact factor: 27.401

8.  Discovery of a Family of Genomic Sequences Which Interact Specifically with the c-MYC Promoter to Regulate c-MYC Expression.

Authors:  Francine Rezzoug; Shelia D Thomas; Eric C Rouchka; Donald M Miller
Journal:  PLoS One       Date:  2016-08-23       Impact factor: 3.240

9.  Cucurbitacin B inhibits human breast cancer cell proliferation through disruption of microtubule polymerization and nucleophosmin/B23 translocation.

Authors:  Suwit Duangmano; Phorntip Sae-Lim; Apichart Suksamrarn; Frederick E Domann; Pimpicha Patmasiriwat
Journal:  BMC Complement Altern Med       Date:  2012-10-12       Impact factor: 3.659

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.